NewslettersDermal Cell NewsUncategorizedVYNE Therapeutics Announces Positive Phase Ib Efficacy Data for FMX114 from Phase Ib/IIa Trial for the Treatment of Mild-to-Moderate Atopic DermatitisBy Justin.choi - April 11, 2022042VYNE Therapeutics Inc. announced positive efficacy results from the Phase Ib segment of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis.[VYNE Therapeutics Inc.] 6445212 AAAAAAAA items 1 apa 0 default asc 1 173855 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Press Release